Beijing Weiming Fuyuan Gene Drug Research Center

Beijing Weiming Fuyuan Gene Drug Research Center is a biotechnology research and development entity operating under the Sinobioway Group (Peking University V-Ming). The center specializes in the industrialization of gene therapies, with a primary focus on recombinant adenovirus-based treatments for oncology. It is most notably associated with the development and clinical support of Gendicine, the world's first commercially approved gene therapy product for head and neck cancer. Located in the Peking University Bio-City, the center integrates molecular biology research with large-scale viral vector manufacturing capabilities. Its work spans from early-stage genetic engineering to the optimization of clinical protocols for gene-based medicines.